Form **PTO-1595** (Rev. 09-08) OMB No. 0651-0027 (exp. 10/31/2008)

۰



103529774

U.S. DEPARTMENT OF COMMERCE United States Patent and Trademark Office

ΞT

To the Director of the U.S. Patent and Trademark Office: Plea	se record the attached documents or the new address(es) below.	
1. Name of conveying party(ies)	2. Name and address of receiving party(ies)	
S.R. One, Limited	Name:OctoPlus Sciences B.V.	
161 Washington Street/8 Tower Bridge, Ste 500 Conshohockenm PA 19428-2077	Internal Address: <u>c/o OctoPlus N.V.</u>	
Additional name(s) of conveying party(ies) attached? 🔀 Yes 🦳 N		
3. Nature of conveyance/Execution Date(s):	Street Address: Zernikedreed 12	
Execution Date(s)October 3, 2008	2333 CL Leiden	
Assignment Merger	Other	
Security Agreement Change of Name	City:	
Joint Research Agreement	State:	
Government Interest Assignment	7	
Executive Order 9424, Confirmatory License	Country: <u>The Netherlands</u> Zip:	
Other Termination of Security Interest	Additional name(s) & address(es) attached? 🔀 Yes 🚺	
	s document is being filed together with a new application	
A. Patent Application No.(s)	B. Patent No.(s)	
11/774,107	5,980,948	
10/493,906	6,730,721	
12/180,214		
Additional numbers a	attached? XYes No	
5. Name and address to whom correspondence concerning document should be mailed:	6. Total number of applications and patents involved: 9	
NameMichele Azzarello	7. Total fee (37 CFR 1.21(h) & 3.41) \$ <u>360.00</u>	
Internal Address:		
Hughes Hubbard & Reed LLP	Authorized to be charged to deposit account	
	∑ Enclosed	
Street Address: One Battery Park Plaza	None required (government interest not affecting title	
City: New York	8. Payment Information	
State: <u>New York</u> Zip10004	-	
State: <u>New York</u> Zip1 <u>0004</u> Phone Number: <u>212-837-6405</u>	- Deposit Account Number	
Phone Number 212-837-6405	- Deposit Account Number - Deposit Account Number - 18/14/2008 MJAMA1 00000045 1177410 - Authorize 000 fer deleme360	
Phone Number: <u>212-837-6405</u> Fax Number: <u>212-299-6405</u>	- 10/14/2008 RJARA1 0000045 1177410	

Documents to be recorded (including cover sheet) should be faxed to (571) 273-0140, or mailed to: Mail Stop Assignment Recordation Services, Director of the USPTO, P.O.Box 1450, Alexandria, V.A. 22313-1450

Page 1 of 4

Continuation of Item No. 1:

Additional Conveying Parties

LSP III Omni Investment Cooperatief U.A. Johannes Vermeerplein 9 1071 DV Amsterdam The Netherlands

Page 2 of 4

Continuation of Item 2:

Additional Receiving Parties

Chienna B.V. c/o OctoPlus N.V. Zernikedreed 12 2333 CL Leiden The Netherlands

OctoPlus Development B.V. c/o OctoPlus N.V. Zernikedreed 12 2333 CL Leiden The Netherlands

OctoPlus Technologies B.V. c/o OctoPlus N.V. Zernikedreed 12 2333 CL Leiden The Netherlands

Page 3 of 4

60413390_1.DOC

Continuation of Item No. 4:

Additional Applications Nos.

60/985,526 60/951,879 60/952,140 60/978,330

Page 4 of 4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

REGISTRANTS/APPLICANTS: OCTOPLUS SCIENCES B.V. CHIENNA B.V. OCTOPLUS DEVELOPMENT B.V. OCTOPLUS TECHNOLOGIES B.V. PATENTS: SEE ATTACHED EXHIBIT A

TERMINATION OF PATENT SECURITY INTEREST

WHEREAS, OCTOPLUS SCIENCES B.V., CHIENNA B.V., OCTOPLUS DEVELOPMENT B.V. AND OCTOPLUS TECHNOLOGIES B.V., private companies with limited liability (*besloten* vennootschappen met beperkte aansprakelijkheid), incorporated and existing under Dutch law (each a "Grantor" and collectively, the "Grantors"), own the patents and applications listed on the attached **Exhibit A**, now issued or pending in the United States Patent and Trademark Office; and

WHEREAS, the Grantors entered into that certain Intellectual Property Security Agreement dated as of May 21, 2008 (the "Security Agreement") among the Grantors, S.R. One, Limited and LSP III Omni Investment Cooperatief U.A. (each a "Security Party" and collectively, "Secured Parties"); a true and correct copy of which was recorded by the the U.S. Patent and Trademark Office on May 30, 2008 at Reel Number 021018 and Frame Number 0559; and

NOW, THEREFORE, pursuant to the Notice of Termination and Release of Pledge of Biolex IP dated as of October <u>3</u>, 2008 among OctoPlus N.V., Grantors, Secured Parties, and Biolex Therapeutics, Inc., for good and valuable consideration, receipt of which is hereby acknowledged, Secured Parties hereby:

1. release and reassign to the Grantors any and all liens, security interests, right, title and interest of Secured Parties pursuant to the Security Agreement in the patents more fully described on **Exhibit A**, without recourse or representation or warranty, express or implied; and

2. authorize and request the Commissioner of Patents and Trademarks of the United States of America to note and record the existence of the release hereby given.

[Signature page follow]

1103271 v2/SF

IN WITNESS WHEREOF, Secured Parties have caused this Termination to be signed by their duly authorized representatives as of this <u>3</u> day of October 2008.

SECURED PARTIES:

S.R. One, Limited



LSP III Omni Investment Cooperatief U.A.

By:		 	
Name:		 	
Title:		 	
Address	s:	 	

1103271 v1/SF

IN WITNESS WHEREOF, Secured Parties have caused this Termination to be signed by their duly authorized representatives as of this 3 day of October 2008.

SECURED PARTIES:

S.R. One,	Limited
-----------	---------

By:	
Name:	
Title:	
Address	3:

LSP III Omni Investment Cooperatief U.A.					
BY: LSP IIL MANAGEMENT B.V.					
Name: M. KLEYWEGT AND B. VAESSEN					
Title: DIRECTOR AND PROFYHOUDER					
Address: JOHANNES VERMEER DLEIN 9 1071 DV AMSTERDAM					
THE NETHERUANS					

ML

1103271 v1/SF

EXHIBIT A

PATENTS

Description	Patent/ Application Number	Owner
Polyetherester copolymers as drug delivery matrices	US5980948	Chienna B.V.
Implant, molding of polymer	US6730721	Chienna B.V.
IFN-alpha depot compositions (Controlled release compositions for interferon based on PEGT/PBT block copolymers)	US11/774,107 (20080008733)	OctoPlus Sciences B.V.
Method for production of purified microparticles	US10/493,906 (20050084536)	OctoPlus Sciences B.V.
Controlled / sustained release IFN drug products and treatment of HCV infection	US60/951879 US60/952140 US60/978330 US60/985526 PCT/US/2008/071191	OctoPlus Sciences B.V. (co-owner)
	US12180214	

1103271 v2/SF

-

RECORDED: 10/14/2008